The FDA recommends Wegovy for weight loss if you meet one of the following criteria: Have a body mass index (BMI) of 27kg/m2 or greater and at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol Have a BMI of 30kg/m2 or greater Avoid semaglutide if you have: History of medullary thyroid cancer History of gallbladder disease History of pancreatitis Multiple endocrine neoplasia syndrome type 2 (MEN2) If youre considering semaglutide for weight loss, your first step should be consulting your primary care physician (PCP)
WEGOVYTM is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Delayed gastric emptying, as is characteristic for all patients with gastroparesis, complicates the use of insulin and optimal diabetes management for many patients
Numerous observational studies have suggested that there is an inverse relationship between vitamin C intake and the risk of developing pancreatic cancer
Subclinical alteration of the cervical-vaginal microbiome in women with idiopathic infertility
The key difference between a GLP-1 agonist and GLP-1 itself is that the drugs are modified to resist quick breakdown, so they last longer in the body than the natural hormone
